relatlimab: Clinical Trials

59 trials of relatlimab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

19 completed, 18 recruiting, 10 active not recruiting, 5 terminated. 59 Phase 2, 12 Phase 1, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 259Completed 19, Recruiting 18, Active not recruiting 10, Terminated 5, Unknown 3, Withdrawn 3, Suspended 1
Phase 112Completed 6, Terminated 3, Recruiting 2, Active not recruiting 1
Phase 33Recruiting 2, Active not recruiting 1

Follow relatlimab: new trials by email Literature Review of relatlimab trials Research Report on relatlimab

Trials (filtered) newest first · largest first

All 59 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer.
Nivolumab, Gemcitabine, Cisplatin - Advanced Biliary Tract Cancer(BTC)
Phase 2WithdrawnNational Health Research Institutes, Taiwan2026-12-012026-07-02
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
Nivolumab and Relatlimab, Melphalan - Metastatic Melanoma, Liver Metastases
Phase 1 / Phase 2RecruitingUniversity of Wisconsin, Madison152026-11-012026-10-30
ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
Nivolumab, Relatlimab, Ipilimumab - Metastatic Melanoma, Advanced Melanoma
Phase 2RecruitingNYU Langone Health902026-04-132026-08-24
Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)
Ipilimumab 3mg/kg and nivolumab 1mg/kg, Ipilimumab 1mg/kg Nivolumab 480mg and relatlimab 160mg, Nivolumab 480mg and relatlimab 160mg - Cutaneous Melanoma, Mucosal Melanoma
Phase 2RecruitingMelanoma Institute Australia4942026-02-092026-02-19
Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab
Nivolumab, Relatlimab, TMZ - Newly Diagnosed Glioblastoma
Phase 2RecruitingDuke University922025-11-282026-09-17
Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma
Nivolumab, Relatlimab plus Nivolumab - Basal Cell Carcinoma
Phase 2RecruitingUniversity of California, San Diego302025-08-212026-07-28
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
LNS8801, Pembrolizumab, Chemotherapy (dacarbazine or temozolomide) - Melanoma (Skin Cancer), Melanoma Stage IIIB-IV
Phase 2 / Phase 3RecruitingLinnaeus Therapeutics, Inc.1352025-08-062026-04-22
Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)
Nivolumab, Relatlimab, Ipilimumab - Melanoma
Phase 1 / Phase 2RecruitingM.D. Anderson Cancer Center302024-12-312026-08-28
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
Biopsy Procedure, Biospecimen Collection, Lomustine - Progressive Glioblastoma, Recurrent Glioblastoma
Phase 2SuspendedNational Cancer Institute (NCI)1842024-11-082026-11-12
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Biospecimen Collection, Bone Scan, Carboplatin - Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma
Phase 2RecruitingNational Cancer Institute (NCI)1562024-07-152026-11-06
Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma
Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination - Cutaneous Squamous Cell Carcinoma
Phase 2RecruitingMelanoma Institute Australia202024-06-212026-07-08
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
Nivolumab, Nivolumab + Relatlimab, Ipilimumab - Melanoma Stage III, Melanoma Stage IV
Phase 2RecruitingH. Lee Moffitt Cancer Center and Research Institute902024-05-172026-04-01
Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma
Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination - Merkel Cell Carcinoma
Phase 2RecruitingMelanoma Institute Australia202024-03-112026-02-17
Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab
Nivolumab, Relatlimab - Urologic Neoplasms, Urogenital Neoplasms
Phase 2Active not recruitingThe Netherlands Cancer Institute902024-02-192026-07-15
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Biospecimen Collection, cfDNA or ctDNA Measurement, Computed Tomography - Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma
Phase 2 / Phase 3RecruitingNational Cancer Institute (NCI)9922024-02-022026-11-12
A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma
Relatlimab and nivolumab fixed dose combination (FDC) - Stage II Melanoma
Phase 2Active not recruitingMelanoma Institute Australia202023-08-142026-02-05
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
BMS-986213 (Relatlimab-Nivolumab FDC), Nivolumab, Relatlimab - Melanoma (Skin)
Phase 2RecruitingM.D. Anderson Cancer Center302023-02-232026-07-16
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
Sarilumab, Ipilimumab Injection, Nivolumab/Relatlimab - Melanoma, Unresectable Melanoma
Phase 2RecruitingNYU Langone Health1052023-02-022026-10-28
Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla
Nivolumab, Relatlimab - Carcinomas, Renal Medullary Carcinoma
Phase 2Active not recruitingM.D. Anderson Cancer Center302022-09-222026-10-07
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
Relatlimab, Nivolumab - Lymphoma, Non-Hodgkin, Hodgkin Disease
Phase 1 / Phase 2TerminatedBristol-Myers Squibb52022-09-132026-06-26

Showing 20 of 59. Sign in to see all of them.

Conditions studied

Melanoma (15)  ·  Neoplasms (4)  ·  Recurrence (4)  ·  Carcinoma, Hepatocellular (3)  ·  Colonic Neoplasms (3)  ·  Colorectal Neoplasms (3)  ·  Lymphoma, Non-Hodgkin (3)  ·  Multiple Myeloma (3)  ·  Stomach Neoplasms (3)  ·  Urinary Bladder Neoplasms (3)  ·  Carcinoma, Basal Cell (2)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Hematologic Neoplasms (2)  ·  Hodgkin Disease (2)  ·  Liver Neoplasms (2)

Sponsors

Bristol-Myers Squibb (15)  ·  M.D. Anderson Cancer Center (5)  ·  National Cancer Institute (NCI) (5)  ·  Melanoma Institute Australia (4)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4)  ·  Dan Zandberg (2)  ·  NYU Langone Health (2)  ·  The Netherlands Cancer Institute (2)  ·  University Hospital, Essen (2)  ·  Celgene (1)  ·  Duke University (1)  ·  Elizabeth Davis (1)  ·  H. Lee Moffitt Cancer Center and Research Institute (1)  ·  Inge Marie Svane (1)  ·  Institut BergoniĆ© (1)

Countries

United States (43)  ·  Australia (18)  ·  Canada (12)  ·  France (12)  ·  Italy (12)  ·  Spain (12)  ·  Germany (11)  ·  Netherlands (9)  ·  United Kingdom (8)  ·  Austria (7)  ·  Belgium (6)  ·  Mexico (6)  ·  Switzerland (6)  ·  Argentina (5)  ·  Brazil (5)

Top investigators

Dung Le, MD (2)  ·  Georgina Long (2)  ·  Ahmad Tarhini, MD, PhD (1)  ·  Arun Singh (1)  ·  Brigette B Ma (1)  ·  Dan P Zandberg, MD (1)  ·  Dan Zandberg, MD (1)  ·  Elizabeth Davis, MD (1)  ·  Evan J Lipson, M.D. (1)  ·  Georgina V Long (1)  ·  Hearn J. Cho, M.D., Ph.D. (1)  ·  Hussein Tawbi, MD, PHD (1)  ·  Hussein Tawbi, MD,PHD (1)  ·  Ines Da Silva (1)

Results publications

PMID 26586415, PMID 28734759, PMID 29355075, PMID 30170630, PMID 31487218, PMID 32251400, PMID 32324435, PMID 32463741, PMID 33048619, PMID 33277223, PMID 34083421, PMID 34515338, PMID 34606846, PMID 34637336, PMID 34986285, PMID 35133871, PMID 35138919, PMID 35969233, PMID 36328377, PMID 36351402, PMID 36628573, PMID 36648215, PMID 36719749, PMID 36780608, PMID 37053535, PMID 37167764, PMID 37322121, PMID 37934000, PMID 38320023, PMID 38340723, PMID 38591867, PMID 38608691, PMID 38689060, PMID 38821718, PMID 38838311, PMID 38838316, PMID 39187595, PMID 39278994, PMID 39666929, PMID 39671533, PMID 39693587, PMID 39889250, PMID 39913886, PMID 40010775, PMID 40016450, PMID 40030000, PMID 40340830, PMID 40513285, PMID 40638872, PMID 40865033

NIH funding

2018 (4), 2016 (2), 2023 (2), U10CA180820 (2), U10CA180821 (2), 2015 (1), 2019 (1), P50CA062924 (1), U10CA180868 (1), U24CA196172 (1)